Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP

December 05, 2020 By The ASCO Post Staff

Emmanuel Bachy, MD, PhD, of the Hospices Civils de Lyon, discusses the final analysis of a phase III study of adding romidepsin to chemotherapy in patients with previously untreated peripheral T-cell lymphoma. Adding romidepsin did not improve progression-free survival and was associated with high rates of adverse events (Abstract 39).

Related Content